Vella C, Minor P D, Weller I V, Jenkins O, Evans D, Almond J
National Institute for Biological Standards and Control, Potters Bar, Herts, UK.
AIDS. 1991 Apr;5(4):425-30. doi: 10.1097/00002030-199104000-00011.
The neutralization of five poliovirus/HIV chimaeras by serum from HIV-infected individuals was examined to evaluate the presentation of HIV envelope sequences, to assess the immune response of individuals to specific epitopes, and to relate it to the stage of disease. The sera were unable to differentiate between four of the chimaeras and the Sabin vaccine strain. With a fifth construct containing an immunodominant gp41 sequence, significant differential recognition was observed in approximately 67% of individuals with asymptomatic HIV infection [groups II and III of the Centers for Disease Control (CDC) classification of HIV infection] and 37% of patients with symptomatic disease (CDC group IV). Furthermore, among patients with CDC stage IV disease antibody levels against this construct and the titre achieved decreased with progression to further disease from approximately 40% in AIDS-related complex (ARC) patients (CDC group IVA and IVC-2 to 14% in those with AIDS (other group IV diseases). Loss of antibody to this construct did not result from a reduction in the anti-polio or anti-envelope response, but from a decline in antibody levels to the HIV sequence inserted in antigenic site 1.
检测了HIV感染个体血清对五种脊髓灰质炎病毒/HIV嵌合体的中和作用，以评估HIV包膜序列的呈现情况，评估个体对特定表位的免疫反应，并将其与疾病阶段相关联。这些血清无法区分其中四种嵌合体和Sabin疫苗株。对于含有免疫显性gp41序列的第五种构建体，在大约67%的无症状HIV感染个体[疾病控制中心（CDC）HIV感染分类的II组和III组]和37%的有症状疾病患者（CDC IV组）中观察到了显著的差异识别。此外，在CDC IV期疾病患者中，针对该构建体的抗体水平以及所达到的滴度随着疾病进展而下降，从艾滋病相关综合征（ARC）患者（CDC IVA组和IVC - 2组）中的约40%降至艾滋病患者（其他IV组疾病）中的14%。针对该构建体抗体的丧失并非源于抗脊髓灰质炎或抗包膜反应的降低，而是由于插入抗原位点1的HIV序列的抗体水平下降。
